Grant: Doctoral Research Award - PA: Hypertension (SHOPP)
University of Toronto
$52,500.00
Clinical application of novel chip-based technology for determination of sphingosine-1-phosphate-dependence of microvessel dysfunction in patients with heart failure
EF 2011-12
Résumé
Cardiovascular disease is the current leading cause of illness and death worldwide, and poses a significant burden on healthcare resources. Small, microscopic blood vessels called resistance arteries critically control blood flow to various organs and overall blood pressure. Animal experiments show that abnormal changes in resistance artery structure and function occur in common cardiovascular diseases such as heart failure. Therefore, it is important to determine how resistance arteries are affected and controlled in order to develop new treatments for cardiovascular disease.
Our lab has discovered that a small molecule called Sphingosine-1-Phosphate (S1P) controls normal resistance artery function in healthy mice. Moreover, S1P activity is abnormally increased in mice with heart failure, causing disease-related changes in resistance artery function. Given these findings, we expect that: 1) increased S1P is also responsible for resistance artery dysfunction in heart failure patients, and 2) blocking increased S1P activity should normalize resistance artery function and produce beneficial effects.
We have also developed a new platform for studying resistance artery function called the Artery-on-a-Chip (AoC) that is more efficient and user-friendly than current standard techniques. We plan to use new AoC technology to test patient blood vessel samples from gut and muscle tissue collected during surgery.
This cutting-edge research represents the first investigation of human gut and muscle resistance artery function in cardiovascular disease patients, and will uncover valuable information that will add to our understanding of what causes heart failure. Correlating human resistance artery function to an individual patient's medical status and history will reveal new diagnostic and therapeutic insights.
This work will lead to the development of innovative technology that may improve and personalize how we treat heart failure.
Programme
Doctoral Research Award - PA: Hypertension (SHOPP)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
245830
Name
Hui Sonya K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Hypertension Canada (Markham, Ontario)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Clinical application of novel chip-based technology for determination of sphingosine-1-phosphate-dependence of microvessel dysfunction in patients with heart failure
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$52,500
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Hypertension (SHOPP)
Keyworddelim
Artery-On-A-Chip Platform; Cardiovascular Disease; Heart Failure; Human Tissue; Microfluidics; Myogenic Response; Resistance Arteries; Sphingosine-1-Phosphate Signaling; Translational Research; Tumour Necrosis Factor-Alpha
Abstract
Cardiovascular disease is the current leading cause of illness and death worldwide, and poses a significant burden on healthcare resources. Small, microscopic blood vessels called resistance arteries critically control blood flow to various organs and overall blood pressure. Animal experiments show that abnormal changes in resistance artery structure and function occur in common cardiovascular diseases such as heart failure. Therefore, it is important to determine how resistance arteries are affected and controlled in order to develop new treatments for cardiovascular disease.
Our lab has discovered that a small molecule called Sphingosine-1-Phosphate (S1P) controls normal resistance artery function in healthy mice. Moreover, S1P activity is abnormally increased in mice with heart failure, causing disease-related changes in resistance artery function. Given these findings, we expect that: 1) increased S1P is also responsible for resistance artery dysfunction in heart failure patients, and 2) blocking increased S1P activity should normalize resistance artery function and produce beneficial effects.
We have also developed a new platform for studying resistance artery function called the Artery-on-a-Chip (AoC) that is more efficient and user-friendly than current standard techniques. We plan to use new AoC technology to test patient blood vessel samples from gut and muscle tissue collected during surgery.
This cutting-edge research represents the first investigation of human gut and muscle resistance artery function in cardiovascular disease patients, and will uncover valuable information that will add to our understanding of what causes heart failure. Correlating human resistance artery function to an individual patient's medical status and history will reveal new diagnostic and therapeutic insights.
This work will lead to the development of innovative technology that may improve and personalize how we treat heart failure.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hui, Sonya K
Approvedterm
3 ans 0 mois
Cihrcontribution2
SPIR~ $52,500~ $0~